NO20044767L - Farmasoytisk formulering med modifisert frigjoring - Google Patents
Farmasoytisk formulering med modifisert frigjoringInfo
- Publication number
- NO20044767L NO20044767L NO20044767A NO20044767A NO20044767L NO 20044767 L NO20044767 L NO 20044767L NO 20044767 A NO20044767 A NO 20044767A NO 20044767 A NO20044767 A NO 20044767A NO 20044767 L NO20044767 L NO 20044767L
- Authority
- NO
- Norway
- Prior art keywords
- modified release
- pharmaceutical formulation
- compound
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201659A SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Modified release pharmaceutical formulation |
PCT/SE2003/000858 WO2003101424A1 (fr) | 2002-05-31 | 2003-05-27 | Formulation pharmaceutique à libération modifiée |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20044767L true NO20044767L (no) | 2005-02-25 |
Family
ID=20288037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20044767A NO20044767L (no) | 2002-05-31 | 2004-11-03 | Farmasoytisk formulering med modifisert frigjoring |
Country Status (23)
Country | Link |
---|---|
US (1) | US7202236B2 (fr) |
EP (1) | EP1513495A1 (fr) |
JP (2) | JP4603353B2 (fr) |
KR (1) | KR101166921B1 (fr) |
CN (2) | CN101264051B (fr) |
AR (1) | AR039936A1 (fr) |
AU (2) | AU2003232870B2 (fr) |
BR (1) | BR0311460A (fr) |
CA (1) | CA2485535C (fr) |
EG (1) | EG24479A (fr) |
IL (1) | IL165029A0 (fr) |
IS (1) | IS7564A (fr) |
MX (1) | MXPA04011914A (fr) |
NO (1) | NO20044767L (fr) |
NZ (1) | NZ536621A (fr) |
PL (1) | PL374299A1 (fr) |
RU (2) | RU2352323C2 (fr) |
SA (1) | SA03240402B1 (fr) |
SE (1) | SE0201659D0 (fr) |
SG (1) | SG165162A1 (fr) |
TW (2) | TWI319317B (fr) |
WO (1) | WO2003101424A1 (fr) |
ZA (1) | ZA200409234B (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
AR034517A1 (es) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
SE0201661D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
SE0201658D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
US7781424B2 (en) * | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
EP1849005A1 (fr) | 2005-01-17 | 2007-10-31 | Gyros Patent Ab | Procede de detection d'une substance a analyser au moins bivalente au moyen de deux reactifs d'affinite |
TW200827336A (en) | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
TW200900033A (en) * | 2007-06-21 | 2009-01-01 | Wen-Qing Li | Automatic brewing machine |
EP2181116A4 (fr) * | 2007-06-25 | 2013-02-27 | Cp Kelco Us Inc | Carraghénine |
US20080317927A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Process for Treatment of Kappa Carrageenan |
US8268808B2 (en) * | 2007-06-25 | 2012-09-18 | Cp Kelco U.S., Inc. | Carrageenan and carrageenan-containing products |
US20080317926A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Carrageenan Process |
US20080317790A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Process for Treatment of Kappa Carrageenan |
US20080317791A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Kappa Carrageenan |
US20080317789A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Carrageenan Process |
US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
CA2702222C (fr) | 2007-10-11 | 2016-08-30 | Richard Fuisz | Produit a base de tabac n'emettant pas de fumee |
US9125434B2 (en) | 2007-10-11 | 2015-09-08 | Philip Morris Products S.A. | Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet |
US20090098192A1 (en) * | 2007-10-11 | 2009-04-16 | Fuisz Richard C | Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same |
JP2011504366A (ja) * | 2007-11-26 | 2011-02-10 | プラント バイオサイエンス リミティド | エンドリシン活性を有する新規ポリペプチド及びその使用 |
US8293285B2 (en) | 2008-03-14 | 2012-10-23 | Cp Kelco U.S., Inc. | Carrageenan modified by ion-exchange process |
US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
GB0908949D0 (en) | 2009-05-26 | 2009-07-01 | Plant Bioscience Ltd | Novel polypeptides having endolysin activity and uses thereof |
EP3512495B1 (fr) | 2016-09-15 | 2022-11-09 | Camurus AB | Formulations d'analogues de prostacycline |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU178398B (en) | 1979-06-12 | 1982-04-28 | Gyogyszerkutato Intezet | Process for producing new agmatine derivatives of activity against haemagglutination |
JPS57149217A (en) | 1981-03-11 | 1982-09-14 | Kaken Pharmaceut Co Ltd | Slow-releasing pharmaceutical preparation |
HU192646B (en) | 1984-12-21 | 1987-06-29 | Gyogyszerkutato Intezet | Process for preparing new n-alkyl-peptide aldehydes |
AU600226B2 (en) | 1985-02-04 | 1990-08-09 | Merrell Pharmaceuticals Inc. | Novel peptidase inhibitors |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US4792452A (en) | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
EP0362002B1 (fr) | 1988-09-01 | 1995-07-26 | Merrell Dow Pharmaceuticals Inc. | Inhibiteurs de protease HIV |
ZA897514B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
TW201303B (fr) | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
CA2075154A1 (fr) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Aldehydes peptidiques utilises comme agents antithrombotiques |
SE9102462D0 (sv) | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
NZ245039A (en) | 1991-11-12 | 1994-12-22 | Lilly Co Eli | N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions |
SE9103612D0 (sv) | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
DE69314478T2 (de) | 1992-03-04 | 1999-02-11 | Gyogyszerkutato Intezet | Neuartige antikoagulierende peptidderivate und arzneimittel die solche enthalten so wie entsprechendes herstellungsverfahren |
TW223629B (fr) | 1992-03-06 | 1994-05-11 | Hoffmann La Roche | |
US5780631A (en) | 1993-06-03 | 1998-07-14 | Astra Aktiebolag | Starting materials in the synthesis of thrombin and kininogenase inhibitors |
SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
SE9301912D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | Process for the production of aminoalkylguandines |
US6984627B1 (en) | 1993-06-03 | 2006-01-10 | Astrazeneca Ab | Peptide derivatives |
EP0648780A1 (fr) | 1993-08-26 | 1995-04-19 | Bristol-Myers Squibb Company | Inhibiteurs hétérocycliques de thrombine |
TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
CA2140598C (fr) | 1994-01-27 | 2010-03-09 | Masahiro Ohshima | Derives de la prolineamide |
US5705487A (en) | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
IL112795A (en) | 1994-03-04 | 2001-01-28 | Astrazeneca Ab | Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them |
US5707966A (en) | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
US5561146A (en) | 1994-06-10 | 1996-10-01 | Bristol-Myers Squibb Company | Modified guanidino and amidino thrombin inhibitors |
DE4421052A1 (de) | 1994-06-17 | 1995-12-21 | Basf Ag | Neue Thrombininhibitoren, ihre Herstellung und Verwendung |
US5498724A (en) | 1994-06-28 | 1996-03-12 | Aktiebolaget Astra | Pyrazoleamidine compounds |
US5510369A (en) | 1994-07-22 | 1996-04-23 | Merck & Co., Inc. | Pyrrolidine thrombin inhibitors |
SK104697A3 (en) | 1995-02-17 | 1998-11-04 | Basf Ag | Novel dipeptide amidines as thrombin inhibitors |
US5710130A (en) | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
US6083532A (en) | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
US5695781A (en) | 1995-03-01 | 1997-12-09 | Hallmark Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers |
JPH11503161A (ja) | 1995-04-04 | 1999-03-23 | メルク エンド カンパニー インコーポレーテッド | トロンビン阻害剤 |
US5629324A (en) | 1995-04-10 | 1997-05-13 | Merck & Co., Inc. | Thrombin inhibitors |
SA96170106A (ar) | 1995-07-06 | 2005-12-03 | أسترا أكتيبولاج | مشتقات حامض أميني جديدة |
AR005245A1 (es) | 1995-12-21 | 1999-04-28 | Astrazeneca Ab | Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion |
SE9601556D0 (sv) | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
SE9602263D0 (sv) | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
WO1997049404A1 (fr) | 1996-06-25 | 1997-12-31 | Eli Lilly And Company | Agents anticoagulants |
SE9602646D0 (sv) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
SE9603724D0 (sv) * | 1996-10-11 | 1996-10-11 | Astra Ab | New pharmaceutical parenteral formulation of a thrombin inhibitor |
AR013084A1 (es) | 1997-06-19 | 2000-12-13 | Astrazeneca Ab | Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados |
IT1297461B1 (it) * | 1997-10-29 | 1999-12-17 | Ciocca Maurizio | Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili |
SE9704543D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
US6251430B1 (en) | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
SE9802938D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
SE9802974D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | New crystalline forms |
SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
AU758178B2 (en) | 1998-09-04 | 2003-03-20 | Scios Inc. | Hydrogel compositions for the controlled release administration of growth factors |
SE9804313D0 (sv) | 1998-12-14 | 1998-12-14 | Astra Ab | New compounds |
CA2355792A1 (fr) | 1999-01-13 | 2000-07-20 | Astrazeneca Ab | Nouveaux derives d'amidinobenzylamine et leur utilisation comme inhibiteurs de thrombine |
SE9902550D0 (sv) | 1999-07-02 | 1999-07-02 | Astra Ab | New crystalline forms |
SE0001803D0 (sv) | 2000-05-16 | 2000-05-16 | Astrazeneca Ab | New compounds i |
PT1311480E (pt) | 2000-08-16 | 2008-11-11 | Astrazeneca Ab | Novos derivados amidino e sua utilização como inibidores da trombina |
SE0003125D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Modified polymers |
SE0102921D0 (sv) | 2001-08-30 | 2001-08-30 | Astrazeneca Ab | Pharmaceutically useful compounds |
AR035216A1 (es) * | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
US7129233B2 (en) | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
AR034517A1 (es) * | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
UA78195C2 (uk) | 2001-08-30 | 2007-03-15 | Astrazeneca Ab | Похідні мигдалевої кислоти та їх застосування як інгібіторів тромбіну, фармацевтична композиція на їх основі |
SE0201658D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
SE0201661D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
-
2002
- 2002-05-31 SE SE0201659A patent/SE0201659D0/xx unknown
-
2003
- 2003-05-27 RU RU2004132856/15A patent/RU2352323C2/ru not_active IP Right Cessation
- 2003-05-27 EP EP03728205A patent/EP1513495A1/fr not_active Withdrawn
- 2003-05-27 JP JP2004508782A patent/JP4603353B2/ja not_active Expired - Fee Related
- 2003-05-27 CN CN200810099130XA patent/CN101264051B/zh not_active Expired - Fee Related
- 2003-05-27 PL PL03374299A patent/PL374299A1/xx unknown
- 2003-05-27 NZ NZ536621A patent/NZ536621A/en not_active IP Right Cessation
- 2003-05-27 US US10/516,420 patent/US7202236B2/en not_active Expired - Fee Related
- 2003-05-27 BR BR0311460-0A patent/BR0311460A/pt not_active IP Right Cessation
- 2003-05-27 CA CA2485535A patent/CA2485535C/fr not_active Expired - Fee Related
- 2003-05-27 CN CNB038124920A patent/CN100402025C/zh not_active Expired - Fee Related
- 2003-05-27 MX MXPA04011914A patent/MXPA04011914A/es active IP Right Grant
- 2003-05-27 WO PCT/SE2003/000858 patent/WO2003101424A1/fr active Application Filing
- 2003-05-27 SG SG200608336-4A patent/SG165162A1/en unknown
- 2003-05-27 RU RU2008142261/15A patent/RU2474416C2/ru not_active IP Right Cessation
- 2003-05-27 KR KR1020047019336A patent/KR101166921B1/ko not_active IP Right Cessation
- 2003-05-27 AU AU2003232870A patent/AU2003232870B2/en not_active Ceased
- 2003-05-30 TW TW092114767A patent/TWI319317B/zh not_active IP Right Cessation
- 2003-05-30 AR ARP030101934A patent/AR039936A1/es not_active Application Discontinuation
- 2003-05-30 TW TW097139255A patent/TWI319318B/zh not_active IP Right Cessation
- 2003-11-22 EG EG2003111045A patent/EG24479A/xx active
- 2003-11-30 SA SA3240402A patent/SA03240402B1/ar unknown
-
2004
- 2004-11-03 NO NO20044767A patent/NO20044767L/no not_active Application Discontinuation
- 2004-11-04 IL IL16502904A patent/IL165029A0/xx unknown
- 2004-11-17 ZA ZA200409234A patent/ZA200409234B/en unknown
- 2004-11-29 IS IS7564A patent/IS7564A/is unknown
-
2009
- 2009-08-06 JP JP2009183614A patent/JP2009298795A/ja active Pending
- 2009-12-04 AU AU2009243524A patent/AU2009243524A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20044767L (no) | Farmasoytisk formulering med modifisert frigjoring | |
SE0202463D0 (sv) | Novel compounds | |
HK1080470A1 (en) | Heterocyclic compounds | |
NO20025821L (no) | 2-aminokarbonyl-9H-purinderivater | |
NO20062292L (no) | Fremgangsmate for behandling av transplantasjonsavstoting | |
CA2478374A1 (fr) | Utilisation de derives de benzimidazole alkyles n3 en tant qu'inhibiteurs de mek | |
HK1079522A1 (en) | Thienyl compounds | |
NO20054852L (no) | GFAT inhibitorer | |
DK1406876T3 (da) | 2-anilinopyrimidinderivater som inhibitorer af cyclinafhængige kinaser | |
DE60334536D1 (de) | Furylverbindungen | |
NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
NO20050667L (no) | N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes | |
SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0104250D0 (sv) | Heterocyclic compounds | |
SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
NO20044810L (no) | Farmasoytisk formulering med oyeblikkelig frigjoring | |
SE0302756D0 (sv) | Novel Compounds | |
SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
DK1109560T3 (da) | Som AICARFT-inhibitorer anvendelige forbindelser | |
SE0203302D0 (sv) | Novel Compounds | |
SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
MXPA02004441A (es) | Derivados de isoxazol como inhibidores de la fosfodiesterasa. | |
MXPA04009421A (es) | Compuestos de tiazol-2-ilimina como inhibidores de la pde-7. | |
NO20041671L (no) | Anthelmintic composition | |
NO20013921L (no) | Heterocykliske derivater som inhibitorer av faktor Xa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |